Beit Jala Pharmaceutical Company reported earnings results for the six months ended June 30, 2018. For the period, the company reported sales of JOD 3,153,744 compared to JOD 3,738,466, net income before tax of JOD 222,790 compared to JOD 645,379 and net income after tax of JOD 206,688 or JOID 0.030 per basic and diluted share compared to JOD 593,336 or JOID 0.085 per basic and diluted share a year ago. Net cash flow from operating activities was JOD 454,515 compared to JOD 1,077,796 and purchase of property, plant and equipment was JOD 381,128 compared to JOD 154,664 a year ago.